| Meadowbrook Of Granby | |
| 350 Salmon Brook Street, Granby, Connecticut 06035 | |
| (860) 653-9888 | |
| Name | Meadowbrook Of Granby |
|---|---|
| Location | 350 Salmon Brook Street, Granby, Connecticut |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 90 |
| Occupancy Rate | 72.67% |
| Medicare ID (CCN) | 075367 |
| Legal Business Name | Athena Meadowbrook Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1134562812 |
| Organization Name | ATHENA MEADOWBROOK, LLC |
| Doing Business As | MEADOWBROOK OF GRANBY |
| Address | 350 Salmon Brook St, Granby, CT 06035 |
| Phone Number | 860-653-9888 |
News Archive
An international research team led by the University of Bonn (Germany) has identified and further developed novel antibody fragments against the SARS coronavirus-2. These "nanobodies" are much smaller than the classic antibodies used to treat US President Donald Trump, for example.
New bioarchaeology research from a University of Otago PhD candidate has shown how infectious diseases may have spread 4000 years ago, while highlighting the dangers of letting such diseases run rife.
Jopari Solutions, the principal supplier of medical EDI services and connectivity networks to Providers and Payers in Property & Casualty markets, and Noble House, a software leader for billing and claims management for DME/HME, today announced a strategic partnership to advance medical billing and processing.
The team behind the Deciphering Developmental Disorders (DDD) Study, one of the world's largest nationwide rare disease genome-wide sequencing initiatives, have developed a novel computational approach to identify genetic variants that cause disease in young children.
Lorus Therapeutics has announced that the EMEA (European Medicines Agency) has given a positive opinion on Lorus' application for orphan drug status to Virulizin, the company's lead anticancer drug for the treatment of pancreatic cancer.
› Verified 5 days ago
| NPI Number | 1770547473 |
| Organization Name | ATHENA MEADOWBROOK, LLC |
| Doing Business As | MEADOWBROOK OF GRANBY |
| Address | 350 Salmon Brook St, Granby, CT 06035 |
| Phone Number | 860-653-9888 |
News Archive
An international research team led by the University of Bonn (Germany) has identified and further developed novel antibody fragments against the SARS coronavirus-2. These "nanobodies" are much smaller than the classic antibodies used to treat US President Donald Trump, for example.
New bioarchaeology research from a University of Otago PhD candidate has shown how infectious diseases may have spread 4000 years ago, while highlighting the dangers of letting such diseases run rife.
Jopari Solutions, the principal supplier of medical EDI services and connectivity networks to Providers and Payers in Property & Casualty markets, and Noble House, a software leader for billing and claims management for DME/HME, today announced a strategic partnership to advance medical billing and processing.
The team behind the Deciphering Developmental Disorders (DDD) Study, one of the world's largest nationwide rare disease genome-wide sequencing initiatives, have developed a novel computational approach to identify genetic variants that cause disease in young children.
Lorus Therapeutics has announced that the EMEA (European Medicines Agency) has given a positive opinion on Lorus' application for orphan drug status to Virulizin, the company's lead anticancer drug for the treatment of pancreatic cancer.
› Verified 5 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
An international research team led by the University of Bonn (Germany) has identified and further developed novel antibody fragments against the SARS coronavirus-2. These "nanobodies" are much smaller than the classic antibodies used to treat US President Donald Trump, for example.
New bioarchaeology research from a University of Otago PhD candidate has shown how infectious diseases may have spread 4000 years ago, while highlighting the dangers of letting such diseases run rife.
Jopari Solutions, the principal supplier of medical EDI services and connectivity networks to Providers and Payers in Property & Casualty markets, and Noble House, a software leader for billing and claims management for DME/HME, today announced a strategic partnership to advance medical billing and processing.
The team behind the Deciphering Developmental Disorders (DDD) Study, one of the world's largest nationwide rare disease genome-wide sequencing initiatives, have developed a novel computational approach to identify genetic variants that cause disease in young children.
Lorus Therapeutics has announced that the EMEA (European Medicines Agency) has given a positive opinion on Lorus' application for orphan drug status to Virulizin, the company's lead anticancer drug for the treatment of pancreatic cancer.
› Verified 5 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 16.16 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 10.45 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 44.44 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.43 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0.46 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 1.75 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 4.08 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 98.78 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 15.55 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 95.6 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.11 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 26.55 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 13.1 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 4.09 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 100 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 80.47 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 94.33 | 82.93 |
News Archive
An international research team led by the University of Bonn (Germany) has identified and further developed novel antibody fragments against the SARS coronavirus-2. These "nanobodies" are much smaller than the classic antibodies used to treat US President Donald Trump, for example.
New bioarchaeology research from a University of Otago PhD candidate has shown how infectious diseases may have spread 4000 years ago, while highlighting the dangers of letting such diseases run rife.
Jopari Solutions, the principal supplier of medical EDI services and connectivity networks to Providers and Payers in Property & Casualty markets, and Noble House, a software leader for billing and claims management for DME/HME, today announced a strategic partnership to advance medical billing and processing.
The team behind the Deciphering Developmental Disorders (DDD) Study, one of the world's largest nationwide rare disease genome-wide sequencing initiatives, have developed a novel computational approach to identify genetic variants that cause disease in young children.
Lorus Therapeutics has announced that the EMEA (European Medicines Agency) has given a positive opinion on Lorus' application for orphan drug status to Virulizin, the company's lead anticancer drug for the treatment of pancreatic cancer.
› Verified 5 days ago
Meadowbrook Of Granby Location: 350 Salmon Brook Street, Granby, Connecticut 06035 Phone: (860) 653-9888 |